Dr. Shujun Yang 杨树军
Chief Physician
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and comprehensive medical treatment of malignant tumors, including chemotherapy and targeted therapy for gastrointestinal cancers, lung cancer, and malignant lymphoma.
Dr. Yang is Director of the First Medical Department and Internal Medicine at Henan Cancer Hospital. A master’s supervisor and Henan academic leader, Dr. Yang graduated from Henan Medical University in 1986. Focus areas include digestive tract malignancies, malignant lymphoma, and geriatric oncology. Recent work includes leading one provincial major research project and participating in three National Natural Science Foundation projects.
Professional roles
- Member, Tumor Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Member, Oncology Physician Branch, Chinese Medical Doctor Association
- Director, Chinese Society of Clinical Oncology (CSCO)
- Chair, Chemotherapy Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Shujun). Papers usually list the name as Shujun Yang or Yang S.
Selected publications
39 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gastrointest Oncol, 2023 (senior author): Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis. PubMed 38196538
- Asia Pac J Clin Oncol, 2023 (senior author): Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study. PubMed 36572661
- Oncol Rep, 2021 (senior author): lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis. PubMed 33432363
- J Cell Mol Med, 2019 (senior author): LncRNA ZEB1-AS1 down-regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma. PubMed 31638344
- Oncol Lett, 2018 (senior author): MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma. PubMed 30127911
- Gynecol Oncol, 2018 (senior author): Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. PubMed 29960711
- J Cancer Res Ther, 2015 (senior author): Expression of activating transcription factor 7 is correlated with prognosis of colorectal cancer. PubMed 26148593
- Mol Clin Oncol, 2014 (senior author): Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. PubMed 25279218
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion